VitaGraft™ Kidney

Personalized Transplant Monitoring

Confidently monitor your kidney transplant patients

Fast turnaround time. Improved outcomes.

VitaGraft™ Kidney is a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA following kidney transplantation.

Dependable and accurate results delivered

Step 1
Post-transplant patient blood sample drawn at transplant facility or local laboratory*

Step 2
Send samples to Oncocyte's CAP/CLIA certified laboratory

Step 3
dd-cfDNA measured using dd-PCR

Step 4
Risk for active rejection reported

Rule out suspected injury

86% of unnecessary biopsies triggered by elevated plasma creatinine in stable patients may be avoided using VitaGraft Kidney dd-cfDNA technology.[1]

Taper immunosuppression

Better personalize the minimum effective dose for each patient.[1]

Detect injury early

Use VitaGraft Kidney with improved turnaround times in for-cause clinical scenarios.[1]

Practical. Fast. Evidence-based.

*For the first test we require a one-time urine sample in addition to blood to set the assay for the patient. Thereafter, we require blood only for all subsequent tests.

ONCOCYTE CORPORATION 2 International Plaza, Ste 510 / Nashville, TN 37217 / www.oncocyte.com / info@oncocyte.com / 949.409.7600

ONCOCYTE™ Where Tomorrow LIVES

MKP-015K-0002 1222

VitaGraft Kidney™

Personalized Transplant Monitoring

Clinical Summary

- **Validated in 345 kidney transplant patients with over 2,570 samples for up to 5 years following transplantation.**[1,2]
- For long-term surveillance, measurement of absolute dd-cfDNA concentrations appears to be superior to dd-cfDNA fractional abundance to minimize false positive results.[1,2]
  - Area Under the Receiver Operating Characteristic (AUC_{ROC}) curve for absolute quantity of dd-cfDNA (cp/mL) showed an increase of 14% compared to relative quantification of dd-cfDNA (%) in discriminating stable phase (n=395) from **biopsy-proven rejection** (n=22).[1]
  - High NPV of 91%* to rule out injury.[1]

*Calculated at 25% prevalence using biopsy-proven samples. n = number of samples

ROC curve comparison of dd-cfDNA (cp/mL) and dd-cfDNA (%)[1]



Association found between increased dd-cfDNA values and low tacrolimus concentrations following kidney transplantation[1]



- **dd-cfDNA (cp/mL) may aid clinical care in finding the minimum effective immunosuppressive dose for kidney transplant patients.[1]**
  - There were a significantly higher proportion of samples with elevated dd-cfDNA (cp/mL) and lower tacrolimus levels (<8µg/L) compared to the samples with higher tacrolimus concentrations.[1]

View our VitaGraft Kidney Report

Clear, concise results provided.
Absolute quantification measured.

We're here to help

Oncocyte Customer Service can answer any questions you have. Please contact us at:

Phone: +1-844-ONCOCYTE (1-844-662-6298)
customer.service@oncocyte.com

We do not want cost to be a barrier for testing, patients can call (844-679-6600) or fax (949-271-4972) to see if they qualify for our financial assistance program.

REFERENCES 1. Oellerich M, Shipkova M, Asendorf T, et al. (2019) Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: Results from a prospective observational study. Am J Transplant 19(11):3087. **2.** Schutz E, Asendorf T, Beck J, et al. (2020) Time-dependent apparent increase in dd-cfDNA percentage in clinically stable patients between one and five years following kidney transplantation. Clin Chem 66(10):1290.

ONCOCYTE CORPORATION 2 International Plaza, Ste 510 / Nashville, TN 37217 / www.oncocyte.com / info@oncocyte.com / 949.409.7600

ONCOCYTE™ Where Tomorrow LIVES

MKP-015K-0002 1222